Cardiome Pharma Corp., through its subsidiaries, operates as a life sciences company that focuses on developing drugs to treat or prevent cardiovascular diseases. The company's lead product includes Vernakalant (iv), a product candidate designed for the treatment of atrial fibrillation following cardiac surgery. It also offers and Vernakalant (oral), a product candidate, which is in Phase 2b clinical study for the prevention of recurrence of atrial fibrillation. It also involves in pre-clinical research and development work on the Artesian projects to attenuate the deleterious effects of the excessive neurohormonal activation that occurs in cardiac dysfunction. Cardiome Pharma Corp. has collaboration and license agreement with Astellas Pharma US, Inc. for the co-development and commercialization of Vernakalant as an intravenous formulation; and an in-licensing agreement with Lilly to develop GED-aPC, an engineered analog of recombinant human activated protein C for cardiogenic shock. The company was founded in 1986. It was formerly known as Nortran Resources, Ltd. and changed its name to Nortran Pharmaceuticals, Inc. in 1992. Further, the company changed its name to Cardiome Pharma Corp. in 2001. Cardiome Pharma is headquartered in Vancouver, Canada.